Drug Details
General Information of the Drug (ID: DR5291) | ||||
---|---|---|---|---|
Name |
4-hydroxy-tamoxifen
|
|||
Synonyms |
4'-hydroxytamoxifen; 82413-23-8; 4-Hydroxy-tamoxifen; (Z)-4'-hydroxytamoxifen; CHEMBL10041; trans-Hydroxytamoxifen; 4-[(Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol; 4-HT; 4-{(1Z)-1-[{4-[2-(dimethylamino)ethoxy]phenyl}(phenyl)methylene]propyl}phenol; 4Hydroxy Tamoxifen; NCGC00091028-01; GTPL2817; SCHEMBL2165503; DTXSID00873019; ZINC8602413; BDBM50180684; NCGC00091028-02; Q27073761; 4 inverted exclamation mark -Hydroxy Tamoxifen (contains up to 10% E isomer); 4-[(Z)-1-[4-(2-dimethylaminoethyloxy)phenyl]-1-phenylbut-1-en-2-yl] phenol; 4HT
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Cyclic Mastalgia [ICD-11: GB23] | Phase 2 | [1] | |
Structure |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C26H29NO2
|
|||
PubChem CID | ||||
Canonical SMILES |
CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=C(C=C3)O
|
|||
InChI |
1S/C26H29NO2/c1-4-25(20-10-14-23(28)15-11-20)26(21-8-6-5-7-9-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3/b26-25-
|
|||
InChIKey |
DODQJNMQWMSYGS-QPLCGJKRSA-N
|
|||
CAS Number |
CAS 82413-23-8
|
|||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Betulinic Acid | Rubus alceifolius | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | PYGO2 | Molecule Info | ||
In-vitro Model | MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | ||
MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
MDA-MB-436 | CVCL_0623 | Invasive breast carcinoma | Homo sapiens | |||
MDA-MB-468 | CVCL_0419 | Breast adenocarcinoma | Homo sapiens | |||
Experimental
Result(s) |
Selective estrogen receptor modulators and betulinic acid act synergistically to target ERalpha and SP1 transcription factor dependent Pygopus expression in breast cancer. | |||||
Epigallocatechin gallate | Hamamelis virginiana | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Biological
Regulation |
Induction | Apoptosis | ||||
In-vitro Model | MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | ||
Experimental
Result(s) |
The synergistic cytotoxicity elicited by the combination of EGCG and 4-OHT results from an earlier induction of apoptosis but this was not caused by an increase in G1-arrest or 4-OHT-mediated changes in the metabolism of EGCG. | |||||
Flavopiridol | Dysoxylum binectariferum | Click to Show/Hide the Molecular Data of This NP | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [4] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Activity | CASP2 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Activity | CASP3 | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Arrest | Cell cycle arrest in G2 phase | ||||
In-vitro Model | MON | CVCL_M846 | Extrarenal rhabdoid tumor | Homo sapiens | ||
G-401 | CVCL_0270 | Rhabdoid tumor of the kidney | Homo sapiens | |||
A-204 | CVCL_1058 | Embryonal rhabdomyosarcoma | Homo sapiens | |||
Experimental
Result(s) |
Combining flavopiridol with 4OH-Tam potently inhibited the growth of RT cells by increasing the ability of either drug alone to induce caspases 2 and 3 thereby causing apoptosis. | |||||
Shikonin | Lithospermum erythrorhizon | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [5] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | BID | Molecule Info |
Pathway MAP
|
|
Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | FAS | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | PIK3CB | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Down-regulation | Loss of mitochondrial membrane potential | ||||
In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
MDA-MB-435S | CVCL_0622 | Breast cancer | Homo sapiens | |||
In-vivo Model | Portions of the suspension (6*106 MCF-7 cells in 0.1 mL) were subcutaneously injected into the right fanks of each female nude mice. | |||||
Experimental
Result(s) |
Shikonin and 4-hydroxytamoxifen synergistically inhibit the proliferation of breast cancer cells through activating apoptosis signaling pathway in vitro and in vivo. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Estrogen receptor (ESR) | Molecule Info | [6] | |
Oestrogen receptor beta (ESR2) | Molecule Info | [6] | ||
KEGG Pathway | Estrogen signaling pathway | Click to Show/Hide | ||
2 | Prolactin signaling pathway | |||
3 | Thyroid hormone signaling pathway | |||
4 | Endocrine and other factor-regulated calcium reabsorption | |||
5 | Proteoglycans in cancer | |||
NetPath Pathway | FSH Signaling Pathway | Click to Show/Hide | ||
2 | EGFR1 Signaling Pathway | |||
3 | RANKL Signaling Pathway | |||
Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | Click to Show/Hide | ||
2 | Signaling events mediated by HDAC Class II | |||
3 | Plasma membrane estrogen receptor signaling | |||
4 | LKB1 signaling events | |||
5 | Regulation of Telomerase | |||
6 | ATF-2 transcription factor network | |||
7 | AP-1 transcription factor network | |||
8 | FOXM1 transcription factor network | |||
9 | Validated nuclear estrogen receptor alpha network | |||
10 | Signaling mediated by p38-alpha and p38-beta | |||
11 | FOXA1 transcription factor network | |||
12 | Validated nuclear estrogen receptor beta network | |||
Reactome | Nuclear signaling by ERBB4 | Click to Show/Hide | ||
2 | Nuclear Receptor transcription pathway | |||
WikiPathways | Estrogen signaling pathway | Click to Show/Hide | ||
2 | Nuclear Receptors Meta-Pathway | |||
3 | Estrogen Receptor Pathway | |||
4 | Signaling by ERBB4 | |||
5 | JAK/STAT | |||
6 | Integrated Pancreatic Cancer Pathway | |||
7 | Leptin signaling pathway | |||
8 | miR-targeted genes in muscle cell - TarBase | |||
9 | Integrated Breast Cancer Pathway | |||
10 | Nuclear Receptors | |||
11 | SIDS Susceptibility Pathways | |||
12 | Ovarian Infertility Genes |